Mushrooms and Leaky Gut: Can They Restore the Gut Barrier?

Gut Barrier Research

3 animal models

Lion's Mane has been tested in three distinct animal models, including non-human primates, making it the most thoroughly characterized mushroom for intestinal barrier research.

Ren et al., Molecular Nutrition & Food Research, 2023

2 pathways

indirect via butyrate + direct via signaling

2025 discovery

King Oyster protected tight junctions in human tissue

No human RCT

all evidence is preclinical or cell-level

Ren et al., Molecular Nutrition & Food Research, 2023

View as image ↗

The gut lining is one cell thick. Keeping it sealed depends on proteins called tight junctions, molecular clamps between adjacent cells that control what passes into the bloodstream. When those clamps fail, bacteria and toxins leak through. That failure is what "leaky gut" (formally: intestinal hyperpermeability) actually means. Research on mushrooms and leaky gut has accelerated in recent years. A 2025 study tested King Oyster mushroom directly against human colonic tissue and found it preserved the tight junctions against a controlled disruption challenge. This article examines what that research found, what earlier studies established, and where the evidence still falls short.

For the broader picture of how mushrooms interact with gut bacteria, how mushrooms feed your gut bacteria provides that context.

What Leaky Gut Actually Is (And What's Breaking the Seal)

Leaky gut (intestinal hyperpermeability) occurs when the proteins that hold gut wall cells together weaken, creating gaps that allow bacteria and toxins into the bloodstream. The three proteins at the center of that seal are ZO-1, occludin, and claudin-1.

ZO-1 is a scaffold protein anchored on the interior of gut cells. It doesn't span the gap between cells directly; instead, it holds the junction structure in place from inside. Occludin and claudin-1 are the transmembrane proteins that actually cross the cell boundary and physically seal the space between adjacent cells. When any of these proteins degrade or are not produced in sufficient quantities, the seal weakens.

What passes through those gaps isn't harmless. Bacterial fragments called lipopolysaccharide (LPS) are present in enormous quantities in a healthy gut and are normally contained there. LPS comes from the outer membrane of gram-negative bacteria. When it escapes into the bloodstream, the immune system treats it like a systemic bacterial infection and mounts an inflammatory response. Chronic low-level LPS in circulation has been associated with metabolic dysfunction, liver inflammation, and neuroinflammation.

The gut barrier also blocks partially digested food proteins, undigested fiber fragments, and other antigens that would provoke immune reactions if they reached circulation. Its failure is not limited to digestive symptoms.

This is the precise target of gut barrier research on mushrooms: not whether mushrooms support "gut health" in general, but whether specific mushroom compounds stabilize or restore the expression of ZO-1, occludin, and claudin-1. For a detailed look at which proteins are affected by which compounds, see mushroom compounds and tight junction protein expression.

The Two Routes Mushrooms Use to Reach the Gut Lining

A 2023 systematic review by Zhao and colleagues synthesized the current understanding of mushroom polysaccharides and gut health across mechanisms, species, and outcomes.^[1] The review identified two distinct routes by which mushroom polysaccharides protect the gut barrier.

Route 1: Indirect, Through Butyrate-Producing Bacteria

Mushroom polysaccharides are the complex carbohydrates in fungal cell walls. Human digestive enzymes cannot break them down. They reach the colon intact, where gut bacteria ferment them. The bacteria that ferment them most efficiently include Bifidobacterium and Lactobacillus species. These are precisely the bacteria that are depleted in people with IBD, IBS, and leaky gut.

That fermentation produces short-chain fatty acids, particularly butyrate. Butyrate is the primary fuel for colonocytes, which are the cells lining the gut wall. Beyond energy, butyrate also directly increases the production of tight junction proteins including occludin and claudin-1. More butyrate means better-expressed tight junction proteins, which means a more intact barrier.

This is the indirect route: mushroom polysaccharides feed butyrate-producing bacteria, which produce butyrate, which tells gut wall cells to make more of the proteins that seal the barrier.

Route 2: Direct Anti-Inflammatory Signaling

Separately from the microbiota route, some mushroom compounds reduce activity in two inflammatory signaling systems: NF-kB and MAPK. When gut cells face stress from a chemical insult, a bile acid surge, or a pathogen, these pathways activate. Chronically activated NF-kB is one of the primary mechanisms through which tight junction proteins are degraded. It acts as an inflammatory switch that, when left on, drives continuous breakdown of the gut barrier.

Mushroom polysaccharides that calm those inflammatory signaling systems preserve tight junction proteins directly, without going through the microbiota route.

The two routes are not competing explanations. Both can operate simultaneously, and both are supported by the studies reviewed below. The indirect route depends on microbial shifts, which take days to weeks. The direct route operates at the signaling level and can respond to acute challenges more quickly.

For a mechanistic deep dive, the gut barrier and mushroom polysaccharides: mechanisms covers both pathways in full.

Lion's Mane: From Mice to Monkeys, the Evidence Accumulates

Hericium erinaceus (Lion's Mane) is the most-studied mushroom species for gut barrier effects, with three distinct animal studies now in the literature.

The foundational study came from Ren and colleagues in 2018. They tested Lion's Mane polysaccharide in mice with DSS-induced colitis, one of the most widely used gut barrier research models.^[2] DSS stands for dextran sulfate sodium, a chemical that destroys the gut lining in mice and produces an IBD-like condition. When the gut barrier fails in DSS colitis, tight junction proteins break down in measurable ways. Ren's team found that Lion's Mane polysaccharide produced three parallel protective effects: reduced oxidative stress, suppressed NF-kB and MAPK signaling, and favorable shifts in gut microbiota composition. Both routes the Zhao 2023 review describes were active simultaneously.

The bigger step came later in 2023. A separate research team (also named Ren, different study) tested Hericium erinaceus mycelium-derived polysaccharide in cynomolgus monkeys, a non-human primate model.^[3] The choice of species matters. Cynomolgus monkeys share substantially more gut anatomy, gut immune function, and microbial ecology with humans than mice do. Primate models provide stronger evidence that a finding is likely to translate. The Hericium polysaccharide alleviated ulcerative colitis and modulated gut microbiota in the animals. No consumer publication has reported on this primate study, and it represents the strongest translational evidence for Lion's Mane and gut barrier function in the current literature.

A third Lion's Mane study addresses a distinct clinical population. Tian and colleagues in 2023 tested Hericium polysaccharides in immunocompromised mice whose gut barriers had been damaged by cyclophosphamide, a chemotherapy drug.^[4] Cyclophosphamide disrupts the gut epithelium as a side effect of treatment, and gut barrier damage during chemotherapy is a clinically recognized problem. Hericium polysaccharides restored tight junction proteins and improved the mucosal architecture in these animals. This is not a colitis model; it is a chemotherapy-induced gut damage model, and the findings are specific to that context.

Three studies. Two types of chemical gut damage model. One primate study. All pointing in the same direction. For the full Lion's Mane and IBD research picture, Lion's Mane for IBD: gastroprotective evidence covers that in depth.

The 2025 King Oyster Discovery: Human Tissue, Bile Acid, and Preserved Tight Junctions

The most mechanistically direct evidence for mushrooms and leaky gut arrived in 2025. Kerezoudi and colleagues tested Pleurotus eryngii (King Oyster mushroom) fermented with human gut microbiota against human colonic tissue under a controlled challenge.^[5]

The setup has two notable features. First, the researchers fermented King Oyster mushroom with actual human fecal microbiota before testing it. This step simulates what happens in a real human colon after eating the mushroom. The fermented material is not raw mushroom; it is what the human gut microbiome produces from the mushroom, which is what actually encounters intestinal cells after consumption.

Second, the disruption challenge was deoxycholic acid, a bile acid. Bile acids are naturally produced during digestion and are usually harmless at normal concentrations. At elevated concentrations, they disrupt tight junction integrity. The researchers used deoxycholic acid as a physiologically realistic way to stress the gut barrier. This is a more relevant challenge than DSS (which is a harsh synthetic chemical not produced by the body), because bile acid fluctuations are something human gut cells actually face.

The fermented King Oyster material preserved tight junction integrity against that challenge. It also modulated immune signaling pathways involved in inflammatory responses.

What this is and is not: this is a cell-level experiment using excised human tissue, not a clinical trial in living people. It tests the direct effect of mushroom fermentate on isolated human gut cells. That is not the same as eating King Oyster mushroom and measuring whether your intestinal permeability improves. But it is substantially closer to human biology than a mouse colitis model, the mechanism is directly relevant to leaky gut, and no competitor publication has reported on it.

When Leaky Gut Meets IBS: A Mushroom Blend Restores What's Missing

A 2025 study by Van Den Broeke and colleagues approached the gut barrier question from a different direction, starting with IBS microbiomes rather than animal models.^[6]

IBS microbiomes have a well-documented problem: they underproduce butyrate. The bacteria most responsible for fermenting fiber into butyrate (Faecalibacterium prausnitzii, Roseburia intestinalis, and related species) are chronically reduced in IBS. Their absence is associated with increased intestinal permeability, because the colonocytes that depend on butyrate for fuel and for tight junction upregulation are not receiving adequate supply.

Van Den Broeke's team took stool samples from IBS patients and used them to create ex vivo microbiome cultures, growing these patients' gut bacteria outside the body in controlled conditions. They then tested whether a mushroom blend (combined with triacetin, a short-chain triglyceride that serves as a butyrate precursor) could restore butyrate production in these dysregulated microbiomes.

It did. The mushroom blend shifted the IBS microbiomes back toward butyrate production.

The significance of this finding is in the population: the test was not in healthy microbiomes with intact butyrate-producing capacity. It was in gut ecosystems that had already lost that capacity. The mushroom blend restored function in a compromised system. This closes the mechanistic loop between mushroom polysaccharides and gut barrier repair specifically in people whose microbiomes are already dysbiotic, which is the population most likely to have intestinal permeability issues.

For more on mushrooms and IBS specifically, mushrooms for IBS: can they help or hurt? covers that research directly. And for the upstream question of how mushrooms shift gut bacteria populations, how mushrooms change your gut microbiome provides the full microbiome picture.

The Honest Limits: What the Evidence Does and Does Not Establish

Every study reviewed in this article is preclinical. The evidence base consists of mouse colitis models, a primate model, a human colonic tissue experiment, and an ex vivo microbiome culture. None is a randomized controlled trial measuring intestinal permeability in people taking mushroom supplements.

Clinical measurement of leaky gut happens through specific tests: the lactulose:mannitol ratio (measuring whether large vs. small molecules permeate the gut differently), TEER (trans-epithelial electrical resistance, measuring the electrical barrier across gut tissue), or serum markers like zonulin and LPS-binding protein. None of the studies above applied these methods to a human population taking mushrooms.

The animal-to-human translation is not guaranteed. Mouse gut anatomy, immune function, and microbial ecology differ from human physiology in ways that matter for gut barrier research. The cynomolgus monkey study (Ren 2023) is closer to human biology, and the Kerezoudi 2025 human tissue study is closer still. But neither answers whether supplementing with a mushroom extract changes measurable gut barrier function in people.

What the evidence establishes:

• Multiple mushroom species protect intestinal barrier integrity in animal colitis models
• The mechanism operates through two identified pathways: microbiota/butyrate and NF-kB/MAPK signaling suppression
• King Oyster mushroom preserved tight junctions in human colonic tissue against a physiologically relevant challenge (2025)
• A mushroom blend restored butyrate production in IBS patient microbiomes ex vivo (2025)
• Lion's Mane has the deepest preclinical evidence base, including a non-human primate model

What it does not establish:

• A specific dose or duration for gut barrier benefits in humans
• Whether any particular mushroom form (whole food, extract, powder, fermented) is more effective
• Whether the preclinical effects translate to measurable permeability improvement in people
• Whether the effects in healthy guts differ from effects in compromised guts

For a full species-by-species review of the preclinical data, mushrooms for intestinal permeability: preclinical evidence provides that map. For the practical polysaccharide evidence summary, mushroom polysaccharides and tight junction protein expression covers the specifics.

The Bottom Line

Mushroom polysaccharides, particularly from Lion's Mane (Hericium erinaceus) and King Oyster (Pleurotus eryngii), have shown gut barrier-protective effects in animal colitis models, a non-human primate model, human colonic tissue (2025), and IBS microbiome cultures (2025). The mechanism is well-characterized through two routes: indirect via butyrate production and direct via anti-inflammatory signaling suppression. No human clinical trial has tested mushrooms specifically for intestinal hyperpermeability. The preclinical case is mechanistically coherent and consistent across species; the human clinical evidence is the gap that remains.

Frequently Asked Questions

Do mushrooms help with leaky gut?

Mushroom polysaccharides have shown gut barrier-protective effects in multiple animal models and, as of 2025, in human colonic tissue experiments. No human clinical trial has tested whether mushroom consumption changes measurable intestinal permeability in people. The preclinical evidence is consistent across multiple species and models, operating through butyrate production and anti-inflammatory signaling. Whether those preclinical effects translate to a clinical benefit in people with leaky gut has not been established.

What mushrooms are best for intestinal permeability?

Lion's Mane (Hericium erinaceus) has the deepest preclinical evidence base for gut barrier effects, with data from mouse colitis models, immunocompromised mice, and a non-human primate model. King Oyster mushroom (Pleurotus eryngii) has the most direct human-tissue evidence, from a 2025 study that preserved tight junction integrity against a bile acid challenge in human colonic tissue. No species has been compared head-to-head in a clinical trial, so ranking by effectiveness in humans is not possible from current data.

Can lion's mane heal leaky gut?

Lion's Mane polysaccharides have restored intestinal barrier integrity in mouse colitis models and alleviated ulcerative colitis in non-human primates (cynomolgus monkeys, 2023). Whether those findings translate to a similar effect in humans with intestinal hyperpermeability has not been tested in a clinical trial. The animal evidence is mechanistically coherent, but "healing leaky gut" implies a clinical outcome in humans that the current data does not establish.

What is the best supplement for leaky gut?

The evidence for gut barrier support is strongest for compounds that increase butyrate production or reduce NF-kB and MAPK inflammatory signaling. Mushroom polysaccharides work through both routes in preclinical models. No supplement, mushroom-derived or otherwise, has clinical trial evidence specifically for intestinal hyperpermeability as a primary endpoint. The human trial data is limited across all categories of gut barrier supplements.

Is there clinical evidence for mushrooms and leaky gut?

Direct clinical evidence, meaning a human randomized controlled trial measuring intestinal permeability before and after mushroom supplementation, does not currently exist. The strongest human-adjacent evidence as of 2025 is a study using human colonic tissue (Kerezoudi et al., Nutrients, 2025) showing that fermented King Oyster mushroom preserved tight junction integrity, and an ex vivo experiment using IBS patient microbiomes showing a mushroom blend restored butyrate production. Both are tissue-level studies, not clinical trials in living people.

Sources & References

1. 1RTHM-01835·Zhao, Jiahui et al. (2023). “The Interaction between Mushroom Polysaccharides and Gut Microbiota and Their Effect on Human Health: A Review..” Biology.Study breakdown →PubMed →↩
2. 2RTHM-00529·Ren, Yilin et al. (2018). “Polysaccharide of Hericium erinaceus attenuates colitis in C57BL/6 mice via regulation of oxidative stress, inflammation-related signaling pathways and modulating the composition of the gut microbiota..” The Journal of nutritional biochemistry.Study breakdown →PubMed →↩
3. 3RTHM-01776·Ren, Zhengyu et al. (2023). “Hericium erinaceus mycelium-Derived Polysaccharide Alleviates Ulcerative Colitis and Modulates Gut Microbiota in Cynomolgus Monkeys..” Molecular nutrition & food research.Study breakdown →PubMed →↩
4. 4RTHM-01803·Tian, Baoming et al. (2023). “Ameliorating effects of Hericium erinaceus polysaccharides on intestinal barrier injury in immunocompromised mice induced by cyclophosphamide..” Food & function.Study breakdown →PubMed →↩
5. 5RTHM-02104·Kerezoudi, Evangelia N et al. (2025). “Pleurotus eryngii Mushrooms Fermented with Human Fecal Microbiota Protect Intestinal Barrier Integrity: Immune Modulation and Signalling Pathways Counter Deoxycholic Acid-Induced Disruption in Healthy Colonic Tissue..” Nutrients.Study breakdown →PubMed →↩
6. 6RTHM-02197·Van den Abbeele, Pieter et al. (2025). “Triacetin and a Mushroom Blend Restore Butyrate Production by IBS Microbiomes Ex Vivo, Thus Promoting Barrier Integrity..” International journal of molecular sciences.Study breakdown →PubMed →↩